MAZE
Maze Therapeutics, Inc.
$24.05
-0.17%
$1.3B
No data for this timeframe.
Vol
Market Cap$1.3B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$464.3M
Inst. Activity12 buys / 8 sells
Insider Activity0B / 16S
Insider Net $-$4.6M
SEC Reports7
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001842295·Prev Close $24.09
Recent Activity
Jun 11, 2026
SEC
Three mega-passive institutional investors (Vanguard, BlackRock, Morgan Stanley) collectively doubled their positions in
INST-CLUSTER — Impact 3/10
Jun 8, 2026
Insider
Andrews Nancy C was granted 18,000 shares
Director
Jun 8, 2026
Insider
HOMCY CHARLES J was granted 18,000 shares
Director
Jun 8, 2026
Insider
Hoppenot Herve was granted 18,000 shares
Director
Jun 3, 2026
SEC
Three Maze Therapeutics insiders sold a combined $1.20M in open-market stock over a 6-day window, including the CEO, Pre
CLUSTER — Impact 4/10
May 22, 2026
SEC
Maze Therapeutics disclosed the resignation of Amy Bachrodt, Senior Vice President of Finance, effective June 1, 2026. T
8-K — Impact 2/10
Inst.
ADAGE CAPITAL PARTNERS GP, — NEW
1,178,000 shares ($35.2M)
Inst.
Woodline Partners LP — TRIM
650,229 shares ($19.4M)
Price Targets
$62.55
+160.1% upside
Strong Buy
Current $24.05
Low $46.00
Median $55.00
High $110.00
11 analysts
$46.00
$110.00
Analyst Ratings
5Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 14, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Mar 31, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Mar 25, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | Truist Securities | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.72 ▲ +7.2% | $-0.82 — $-0.44 | 7% YoY | 7 |
| Next Q | $-0.78 ▼ -2.6% | $-0.88 — $-0.64 | -18% YoY | 7 |
| Current FY | $-2.77 ▲ +0.5% | $-3.07 — $-2.29 | 9% YoY | 7 |
| Next FY | $-3.31 ▲ +5.1% | $-4.68 — $-2.33 | -19% YoY | 7 |
Latest Reports
NEUTRAL
INST-CLUSTER
3/10
Three mega-passive institutional investors (Vanguard, BlackRock, Morgan Stanley) collectively doubled their positions in
Jun 11, 2026
BEARISH
CLUSTER
4/10
Three Maze Therapeutics insiders sold a combined $1.20M in open-market stock over a 6-day window, including the CEO, Pre
Jun 3, 2026
BULLISH
Press
8/10
Maze Therapeutics reported positive Phase 2 HORIZON trial data for MZE829 in APOL1-mediated kidney disease (AMKD), showi
Mar 25, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| JANUS HENDERSON GROUP PLC | $85.3M | DOUBLED |
| BlackRock, Inc. | $76.7M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $42.9M | — |
| ADAGE CAPITAL PARTNERS GP, | $35.2M | NEW |
| FMR LLC | $25.8M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Andrews Nancy | A | $0.00 |
| Jun 8, 2026 | HOMCY CHARLES | A | $0.00 |
| Jun 8, 2026 | Hoppenot Herve | A | $0.00 |
| Jun 8, 2026 | Lim Jonathan | A | $0.00 |
| Jun 8, 2026 | SCHELLER RICHARD | A | $0.00 |
50 institutional holders with $464.3M total value (15,533,482 shares) as of 2026-Q1. Top holders: JANUS, BlackRock,, VANGUARD. Net buying activity: 12 institutions added/increased vs 8 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 2,858,876 | $85.3M | 18.4% | DOUBLED +318.0% |
| 2 | BlackRock, Inc. | 2,570,425 | $76.7M | 16.5% | ADD +73.8% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1,435,656 | $42.9M | 9.2% | — |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,178,000 | $35.2M | 7.6% | NEW |
| 5 | FMR LLC | 864,214 | $25.8M | 5.6% | — |
| 6 | CITADEL ADVISORS LLC | 775,714 | $23.2M | 5.0% | — |
| 7 | Woodline Partners LP | 650,229 | $19.4M | 4.2% | TRIM -37.2% |
| 8 | STATE STREET CORP | 636,722 | $19.0M | 4.1% | ADD +38.6% |
| 9 | DRIEHAUS CAPITAL MANAGEMENT LLC | 636,162 | $19.0M | 4.1% | ADD +68.3% |
| 10 | BALYASNY ASSET MANAGEMENT L.P. | 461,151 | $13.8M | 3.0% | DOUBLED +131.5% |
| 11 | FARALLON CAPITAL MANAGEMENT LLC | 373,000 | $11.1M | 2.4% | NEW |
| 12 | MARSHALL WACE, LLP | 310,639 | $9.3M | 2.0% | TRIM -63.3% |
| 13 | GOLDMAN SACHS GROUP INC | 279,713 | $8.3M | 1.8% | — |
| 14 | Freestone Grove Partners LP | 234,953 | $7.0M | 1.5% | ADD +97.6% |
| 15 | MORGAN STANLEY | 204,831 | $6.1M | 1.3% | DOUBLED +569.5% |
| 16 | VANGUARD PORTFOLIO MANAGEMENT LLC | 195,542 | $5.8M | 1.3% | — |
| 17 | BANK OF AMERICA CORP /DE/ | 195,084 | $5.8M | 1.3% | DOUBLED +961.3% |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 186,433 | $5.6M | 1.2% | DOUBLED +123.4% |
| 19 | VANGUARD FIDUCIARY TRUST CO | 151,000 | $4.5M | 1.0% | — |
| 20 | Holocene Advisors, LP | 136,168 | $4.1M | 0.9% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 1,178,000 | — | $35.2M | 2026-Q1 |
| Woodline Partners LP | TRIM | 1,035,229 | 650,229 | -37.2% | $19.4M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | ADD | 378,015 | 636,162 | +68.3% | $19.0M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 199,212 | 461,151 | +131.5% | $13.8M | 2026-Q1 |
| FARALLON CAPITAL MANAGEMENT LLC | NEW | — | 373,000 | — | $11.1M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 847,472 | 310,639 | -63.3% | $9.3M | 2026-Q1 |
| Freestone Grove Partners LP | ADD | 118,876 | 234,953 | +97.6% | $7.0M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 18,381 | 195,084 | +961.3% | $5.8M | 2026-Q1 |
| Alyeska Investment Group, L.P. | TRIM | 196,124 | 100,000 | -49.0% | $3.0M | 2026-Q1 |
| Invesco Ltd. | TRIM | 134,033 | 86,419 | -35.5% | $2.6M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 22,545 | 32,526 | +44.3% | $970.9K | 2026-Q1 |
| RHUMBLINE ADVISERS | ADD | 23,731 | 31,513 | +32.8% | $940.7K | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 15,522 | 20,263 | +30.5% | $604.9K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 27,100 | 15,800 | -41.7% | $471.6K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | 6,897 | 14,570 | +111.3% | $434.9K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | TRIM | 31,295 | 12,416 | -60.3% | $370.6K | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 19,100 | 9,420 | -50.7% | $281.2K | 2026-Q1 |
| STRS OHIO | TRIM | 11,200 | 6,300 | -43.7% | $188.1K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 204 | 1,404 | +588.2% | $41.9K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 5 | 14 | +180.0% | $418.00 | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | DOUBLED | 751,874 | 3,142,587 | +318.0% | $130.2M | 2025-Q4 |
| BlackRock, Inc. | ADD | 1,316,016 | 2,287,155 | +73.8% | $94.8M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 1,334,955 | 1,697,015 | +27.1% | $70.3M | 2025-Q4 |
| STATE STREET CORP | ADD | 384,702 | 533,005 | +38.6% | $22.1M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 433,725 | 199,212 | -54.1% | $8.3M | 2025-Q4 |
13 unique insiders with 45 transactions. Net insider value: -$4.6M ($0.00 bought, $4.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Andrews Nancy C | Director | AWARD | 18,000 | — | — |
| Jun 8, 2026 | HOMCY CHARLES J | Director | AWARD | 18,000 | — | — |
| Jun 8, 2026 | Hoppenot Herve | Director | AWARD | 18,000 | — | — |
| Jun 8, 2026 | Lim Jonathan E | Director | AWARD | 18,000 | — | — |
| Jun 8, 2026 | SCHELLER RICHARD H | Director | AWARD | 18,000 | — | — |
| Jun 8, 2026 | SPIEGELMAN DANIEL K | Director | AWARD | 18,000 | — | — |
| Jun 1, 2026 | Bernstein Harold | President, R&D & CMO | EXERCISE | 14,853 | $10.42 | $154.8K |
| Jun 1, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 13,253 | $25.57 | $338.9K |
| Jun 1, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 6,090 | $26.20 | $159.5K |
| May 29, 2026 | Dandekar Atul | CSBO | SELL | 7,500 | $26.34 | $197.6K |
| May 29, 2026 | Dandekar Atul | CSBO | EXERCISE | 7,500 | $10.42 | $78.2K |
| May 26, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 25,582 | $26.02 | $665.5K |
| May 22, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 4,504 | $26.00 | $117.1K |
| May 15, 2026 | Coloma Jason V | Chief Executive Officer | SELL | 1,822 | $26.00 | $47.4K |
| May 14, 2026 | Bernstein Harold | President, R&D & CMO | EXERCISE | 15,000 | $10.42 | $156.3K |
| May 14, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 15,000 | $26.22 | $393.4K |
| May 4, 2026 | Dandekar Atul | CSBO | EXERCISE | 8,320 | $10.42 | $86.7K |
| May 4, 2026 | HOMCY CHARLES J | Director | GIFT | 7,422 | — | — |
| Apr 29, 2026 | Dandekar Atul | CSBO | EXERCISE | 7,500 | $10.42 | $78.2K |
| Apr 29, 2026 | Dandekar Atul | CSBO | SELL | 7,500 | $25.37 | $190.3K |
| Apr 1, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 11,352 | $29.24 | $331.9K |
| Apr 1, 2026 | Bachrodt Amy | SVP, Finance | SELL | 2,200 | $29.32 | $64.5K |
| Apr 1, 2026 | Bachrodt Amy | SVP, Finance | EXERCISE | 2,500 | $10.42 | $26.1K |
| Apr 1, 2026 | Bernstein Harold | President, R&D & CMO | EXERCISE | 15,000 | $10.42 | $156.3K |
| Mar 30, 2026 | Dandekar Atul | CSBO | SELL | 6,710 | $29.26 | $196.3K |
| Mar 30, 2026 | Dandekar Atul | CSBO | EXERCISE | 7,500 | $10.42 | $78.2K |
| Mar 27, 2026 | Kumar Neil | Director | AWARD | 33,417 | — | — |
| Mar 20, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 6,161 | $48.20 | $297.0K |
| Mar 20, 2026 | Bernstein Harold | President, R&D & CMO | EXERCISE | 15,000 | $10.42 | $156.3K |
| Mar 10, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 29,652 | $50.45 | $1.5M |
| Mar 10, 2026 | Bernstein Harold | President, R&D & CMO | EXERCISE | 30,000 | $10.42 | $312.6K |
| Mar 2, 2026 | Bernstein Harold | President, R&D & CMO | AWARD | 48,000 | — | — |
| Mar 2, 2026 | Bernstein Harold | President, R&D & CMO | AWARD | 24,000 | — | — |
| Mar 2, 2026 | Tahir Misbah | Chief Financial Officer | AWARD | 40,000 | — | — |
| Mar 2, 2026 | Tahir Misbah | Chief Financial Officer | AWARD | 20,000 | — | — |
| Mar 2, 2026 | Coloma Jason V | Chief Executive Officer | AWARD | 150,000 | — | — |
| Mar 2, 2026 | Coloma Jason V | Chief Executive Officer | AWARD | 75,000 | — | — |
| Mar 2, 2026 | Courtney Phillips | GC and Corp. Secretary | AWARD | 32,000 | — | — |
| Mar 2, 2026 | Courtney Phillips | GC and Corp. Secretary | AWARD | 16,000 | — | — |
| Feb 2, 2026 | Bachrodt Amy | SVP, Finance | EXERCISE | 4,844 | $10.42 | $50.5K |
| Feb 2, 2026 | Bachrodt Amy | SVP, Finance | SELL | 200 | $44.15 | $8.8K |
| Feb 2, 2026 | Bernstein Harold | President, R&D & CMO | EXERCISE | 15,000 | $10.42 | $156.3K |
| Feb 2, 2026 | Bernstein Harold | President, R&D & CMO | SELL | 600 | $44.21 | $26.5K |
| Jan 29, 2026 | Dandekar Atul | CSBO | EXERCISE | 7,500 | $10.42 | $78.2K |
| Jan 29, 2026 | Dandekar Atul | CSBO | SELL | 1,200 | $43.18 | $51.8K |
7 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 5 neutral. Avg impact: 3.7/10.
NEUTRAL
INST-CLUSTER
3/10
Three mega-passive institutional investors (Vanguard, BlackRock, Morgan Stanley) collectively double
Jun 11, 2026
BEARISH
CLUSTER
4/10
Three Maze Therapeutics insiders sold a combined $1.20M in open-market stock over a 6-day window, in
Jun 3, 2026
NEUTRAL
8-K
2/10
Maze Therapeutics disclosed the resignation of Amy Bachrodt, Senior Vice President of Finance, effec
May 22, 2026
NEUTRAL
CLUSTER
3/10
CEO Jason Coloma and President/CMO Harold Bernstein sold a combined $441K in open-market shares with
May 18, 2026
NEUTRAL
8-K
4/10
Maze Therapeutics reported Q1 2026 results with a net loss of $24.2M ($0.45/share), narrower than th
May 12, 2026
MIXED
PRESS-RELEASE
5/10
Maze Therapeutics reported Q1 2026 net loss of $24.2M ($0.45/share), missing consensus of $0.43/shar
May 12, 2026
NEUTRAL
424B5
5/10
Maze Therapeutics is raising $145.7 million through a public offering of 5.54 million shares and 850
Apr 22, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 5 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$62.55 mean target
+160.1% upside
Strong Buy (3.00)
$46.00 Low
$110.00 High
| Metric | Value |
|---|---|
| Current Price | $24.05 |
| Target Low | $46.00 |
| Target Mean | $62.55 |
| Target Median | $55.00 |
| Target High | $110.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.72 | $-0.82 | $-0.44 | 7.1% | +7.2% | 4↑ 3↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.78 | $-0.88 | $-0.64 | -17.8% | -2.6% | 3↑ 4↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-2.77 | $-3.07 | $-2.29 | 9.3% | +0.5% | 3↑ 3↓ | $0.0B | 0.0% | 7 |
| Next FY 2027-12-31 |
$-3.31 | $-4.68 | $-2.33 | -19.5% | +5.1% | 4↑ 3↓ | $0.0B | -51.3% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.716 | |
| 7d ago | $-0.775 | +0.060 |
| 30d ago | $-0.771 | +0.056 |
| 60d ago | $-0.804 | +0.089 |
| 90d ago | $-0.788 | +0.073 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 14, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Mar 25, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Truist Securities | INITIATE | — | Buy |
| Mar 16, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Mizuho | INITIATE | — | Outperform |
| Mar 9, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 4, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 16, 2026 | BTIG | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 27, 2026
other
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
<p align="left">SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceut
May 20, 2026
earnings_calendar
MAZE Q1 2026 Earnings Scheduled — 2026-05-20
May 13, 2026
earnings_calendar
MAZE Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
<p align="center"><em>Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support adva
May 11, 2026
earnings_calendar
MAZE Q1 2026 Earnings Scheduled — 2026-05-11
Apr 22, 2026
other
Maze Therapeutics Announces $150 Million Registered Offering
<p align="justify">SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricin
Apr 14, 2026
short_interest
FTD: MAZE — 50,000 shares ($1.4M) failed to deliver
Settlement: 20260414, Price: $27.42, FTD Value: $1,371,000, MAZE THERAPEUTICS INC COM
Apr 6, 2026
earnings_calendar
MAZE Q4 2025 Earnings Scheduled — 2026-04-06
Mar 26, 2026
short_volume
Short Volume: MAZE — 56.7% short (0.5M / 0.8M)
Short: 451,575 | Exempt: 17,029 | TRF Vol: 796,023 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Mar 25, 2026
earnings
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
<p align="center"><em>Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad
Mar 25, 2026
short_interest
FTD: MAZE — 10,522 shares ($0.5M) failed to deliver
Settlement: 20260325, Price: $49.00, FTD Value: $515,578, MAZE THERAPEUTICS INC COM
Mar 20, 2026
short_interest
FTD: MAZE — 20,307 shares ($1.0M) failed to deliver
Settlement: 20260320, Price: $49.43, FTD Value: $1,003,775.01, MAZE THERAPEUTICS INC COM
Mar 6, 2026
short_interest
FTD: MAZE — 44,221 shares ($2.0M) failed to deliver
Settlement: 20260306, Price: $45.30, FTD Value: $2,003,211.3, MAZE THERAPEUTICS INC COM
Mar 5, 2026
short_interest
FTD: MAZE — 39,742 shares ($1.8M) failed to deliver
Settlement: 20260305, Price: $46.48, FTD Value: $1,847,208.16, MAZE THERAPEUTICS INC COM
Mar 3, 2026
short_interest
FTD: MAZE — 29,983 shares ($1.4M) failed to deliver
Settlement: 20260303, Price: $45.61, FTD Value: $1,367,524.63, MAZE THERAPEUTICS INC COM